ImmunityBio's ANKTIVA Plus BCG Shows 71% Complete Response Rate in Bladder Cancer Study
ImmunityBio announced published Phase 2/3 results in the Journal of Urology showing durable responses with ANKTIVA combined with BCG in bladder cancer. The study involved patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Long-term findings showed